LPAL2, lipoprotein(a) like 2, pseudogene, 80350

N. diseases: 53; N. variants: 12
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0042721
Disease: Viral hepatitis
Viral hepatitis 		0.010 Biomarker group BEFREE Thus, the therapeutic effect of ApoA-II could be useful for patients with CD4 T cell-related autoimmune and viral hepatitis. 21300819 2011
CUI: C0042384
Disease: Vasculitis
Vasculitis 		0.010 Biomarker disease BEFREE We identified vasculitis-associated apolipoprotein A-II (VAP2) as a target molecule of the clone and confirmed the independently-established VAP2 antibodies were also therapeutic in SCG/Kj mice. 30787596 2019
CUI: C0202236
Disease: Triglycerides measurement
Triglycerides measurement 		0.100 GeneticVariation phenotype GWASDB Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. 23063622 2012
CUI: C0039292
Disease: Tangier Disease
Tangier Disease 		0.020 Biomarker disease BEFREE In order to test the hypothesis that Tangier patients have abnormal apoA-I or apoA-II, the in vitro lipoprotein binding and in vivo metabolic characteristics of these proteins isolated from normal and Tangier plasma, were studied in normal subjects and patients with Tangier disease. 7130397 1982
CUI: C0039292
Disease: Tangier Disease
Tangier Disease 		0.020 Biomarker disease BEFREE This structural change in apoA-I Tangier is associated with rapid catabolism of apoA-I Tangier-and apoA-II Tangier-containing plasma lipoproteins, and it leads to the deficiency in high density lipoproteins, abnormal chylomicron remnants, and the intracellular accumulation of cholesterol ester characteristic of Tangier disease. 6806810 1982
CUI: C0221014
Disease: Reactive systemic amyloidosis
Reactive systemic amyloidosis 		0.010 Biomarker disease BEFREE Herein, we employed apolipoprotein A-II (ApoA-II) deficient (Apoa2 <sup>-/-</sup> ) and transgenic (Apoa2Tg) mice to investigate the potential roles of ApoA-II in lipoprotein particle formation and progression of AA amyloidosis during APR. 29618729 2018
CUI: C1867743
Disease: Premature coronary artery atherosclerosis
Premature coronary artery atherosclerosis 		0.010 GeneticVariation phenotype BEFREE The MspI restriction fragment length polymorphism 3' to the apolipoprotein A-II gene: relationships with lipids, apolipoproteins, and premature coronary artery disease. 1352975 1992
CUI: C0030409
Disease: Paracoccidioidomycosis
Paracoccidioidomycosis 		0.010 AlteredExpression disease BEFREE Ceruloplasmin, transferrin and apolipoprotein A-II play important role in treatment's follow-up of paracoccidioidomycosis patients. 30359420 2018
CUI: C2712907
Disease: obsolete Combined hyperlipidemia
obsolete Combined hyperlipidemia 		0.020 Biomarker disease BEFREE The aim of this study was to determine whether a fibrate-induced PPARalpha activation corrects the combined hyperlipidemia present in human apoA-II transgenic mice. 16226489 2005
CUI: C2712907
Disease: obsolete Combined hyperlipidemia
obsolete Combined hyperlipidemia 		0.020 AlteredExpression disease BEFREE We conclude that the overexpression of human apoA-II in transgenic mice induces combined hyperlipidemia through an increase in VLDL production. 11082533 2000
CUI: C0028754
Disease: Obesity
Obesity 		0.010 GeneticVariation disease BEFREE Apolipoprotein A-II polymorphism: relationships to behavioural and hormonal mediators of obesity. 21386805 2012
CUI: C0948242
Disease: Nuchal bleb, familial
Nuchal bleb, familial 		0.010 Biomarker disease BEFREE Thus, this locus may have pleiotropic effects on apoA-II and FCH traits. 12738753 2003
CUI: C0027719
Disease: Nephrosclerosis
Nephrosclerosis 		0.010 GeneticVariation disease BEFREE Irrespective of diet, RAGE<sup>-/-</sup> mice were significantly protected against nephrosclerosis lesions (hyalinosis, tubular atrophy, fibrosis and glomerular sclerosis) and renal senile apolipoprotein A-II (ApoA-II) amyloidosis (p < 0.001). 30794349 2019
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X 		0.010 Biomarker disease BEFREE More clinical studies are necessary to clarify the role of apolipoprotein A-II in well-characterized subsets of patients and in the insulin resistance syndrome. 12642785 2003
CUI: C0011570
Disease: Mental Depression
Mental Depression 		0.010 Biomarker disease BEFREE Apolipoprotein A-II was also associated with FSS (P = .022). sNfL, CCL5, CCL18, sICAM-1, and sVCAM-1 levels were not associated with fatigue after adjusting for disability and depression. 31307953 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.020 Biomarker disease BEFREE The primary translation product of human apolipoprotein A-II was purified from wheat germ and ascites cell-free lysates programmed with RNA isolated from either a hepatocellular carcinoma cell line (HepG2) or intestinal epithelium. 6315718 1983
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.020 Biomarker disease BEFREE In addition to the overexpression of AFP, these genes (increased in the presence of HCC) are involved in many processes, such as transcription and protein biosynthesis (HNRPDL, PABPC1, POLR2K, SRP9, SNRPA, and six ribosomal protein genes including RPL8, RPL14, RPL41, RPS5, RPS17, RPS24), the metabolism of lipids and proteins (FADS1, ApoA-II, ApoM, FTL), cell proliferation (Syndecan-2, and Annexin A2), and signal transduction (LRRC28 and FMR1). 17786358 2007
CUI: C1096202
Disease: Lipoprotein (a) measurement
Lipoprotein (a) measurement 		0.100 GeneticVariation phenotype GWASCAT Genome- and exome-wide association study of serum lipoprotein (a) in the Jackson Heart Study. 26377243 2015
CUI: C1096202
Disease: Lipoprotein (a) measurement
Lipoprotein (a) measurement 		0.100 GeneticVariation phenotype GWASCAT A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms. 28512139 2017
CUI: C0154251
Disease: Lipid Metabolism Disorders
Lipid Metabolism Disorders 		0.020 Biomarker group BEFREE Apolipoprotein A-II: beyond genetic associations with lipid disorders and insulin resistance. 12642785 2003
CUI: C0154251
Disease: Lipid Metabolism Disorders
Lipid Metabolism Disorders 		0.020 GeneticVariation group BEFREE The aim of this study was to investigate the effect of -265T/C APOA II polymorphism and saturated fatty acids (SFA) intake interaction on lipid profile in diabetic population who are at risk for lipid disorders. 26210798 2016
CUI: C0023195
Disease: Lecithin Acyltransferase Deficiency
Lecithin Acyltransferase Deficiency 		0.010 Biomarker disease BEFREE We investigated the metabolism of the HDL apolipoproteins (apo) apoA-I and apoA-II in a total of five patients with LCAT deficiency, one with classic LCAT deficiency and four with Fish-eye disease. 8282802 1994
CUI: C3888506
Disease: LDLR mutation
LDLR mutation 		0.010 GeneticVariation disease BEFREE Strikingly lower total cholesterol and LDL-cholesterol values were observed among the majority of the LDLR mutation carriers who were simultaneously homozygous for the -265C variant of apoA-II (total cholesterol: 324 +/- 8 vs 244 +/- 19 mg/dl, P = 0.0015; LDL-cholesterol: 237 +/- 8 vs 155 +/- 18 mg/dl, P = 0.0008). 12522687 2002
CUI: C3714619
Disease: Insulin resistance syndrome
Insulin resistance syndrome 		0.010 Biomarker disease BEFREE More clinical studies are necessary to clarify the role of apolipoprotein A-II in well-characterized subsets of patients and in the insulin resistance syndrome. 12642785 2003
CUI: C0020557
Disease: Hypertriglyceridemia
Hypertriglyceridemia 		0.040 GeneticVariation phenotype BEFREE Body mass index, insulin resistance, mutations in other candidate genes (Asn291Ser and Asp9Asn in the LPL gene, apoE isoforms, polymorphisms in the apoA-II gene and in the apoAI-CIII-AIV gene cluster, and in the IRS-1 gene) could be ruled out as possible factors contributing to the expression of hypertriglyceridemia in this family. 10787434 2000